BioMarin Pharmaceutical Inc. (BMRN) shares rose 19.51%, climbing $10.13 to $62.08, after the company announced a definitive agreement to acquire Amicus Therapeutics for about $4.8 billion in cash.
The deal values Amicus at $14.50 per share, representing a significant premium to its recent trading price, and is expected to expand BioMarin's portfolio with key rare-disease therapies, including Galafold for Fabry disease and Pombiliti + Opfolda for Pompe disease, thereby strengthening its commercial reach.
On the day of the announcement, BMRN opened near its previous close, rallied to an intraday high above $62, and saw unusually heavy trading volume, reflecting strong investor interest tied to the strategic acquisition.
BioMarin said the transaction is expected to accelerate revenue growth, diversify its rare-disease drug portfolio, and be accretive to earnings within the first year after closing, which is anticipated in the second quarter of 2026, subject to customary closing conditions.
52-Week Range: BMRN has shown significant volatility as pipeline data and corporate developments have influenced sentiment throughout the year.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.